Publications by authors named "N A Wilmes"
Cardiovascular disease (CVD) is the number one cause of death worldwide, with hypertension as the leading risk factor for both sexes. As sex may affect responsiveness to antihypertensive compounds, guidelines for CVD prevention might necessitate divergence between females and males. To this end, we studied the effectiveness of calcium channel blockers (CCB) on blood pressure (BP), heart rate (HR) and cardiac function between sexes.
View Article and Find Full Text PDFArticle Synopsis
- The COVID-19 pandemic challenged researchers to respond quickly, raising concerns about the quality of research due to potential lapses in privacy and data protection practices globally.
- A systematic review of studies on hospitalized COVID-19 patients found that only 21.3% reported informed consent, with the highest rates in clinical trials and lowest in retrospective cohort studies; ethical approval was prevalent at 90.9% of studies.
- The review highlighted significant gaps in data anonymization (17%) and data sharing practices (1.2%), indicating ongoing issues with transparency and adherence to quality standards in the pandemic research landscape.
Aims: In the prevention of cardiovascular morbidity and mortality, early recognition and adequate treatment of hypertension are of leading importance. However, the efficacy of antihypertensives may be depending on sex disparities. Our objective was to evaluate and quantify the sex-diverse effects of beta-blockers (BB) on hypertension and cardiac function.
View Article and Find Full Text PDFBackground: The leading global risk factor for cardiovascular-disease-related morbidity and mortality is hypertension. In the past decade, attention has been paid to increase females' representation. The aim of this study is to investigate whether the representation of females and presentation of sex-stratified data in studies investigating the effect of antihypertensive drugs has increased over the past decades.
View Article and Find Full Text PDF